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FusakoWaki,1 Kazuhiro Masuoka,2 Takahiro Fukuda,1 Yoshinobu Kanda,3 Mika Nakamae,4
Kimikazu Yakushijin,5 Katsuhiro Togami,6 Kaichi Nishiwaki,7 Yasunori Ueda,8
Fumio Kawano,9 Masaharu Kasai,10 Koji Nagafuji,11 Maki Hagihara,12 Kazuo Hatanaka,13
Masafumi Taniwaki,14 Yoshinobu Maeda,15 Naoki Shirafuji,16 Takehiko Mori,17
Atae Utsunomiya,18 Tetsuya Eto,19 Hitoshi Nakagawa,20 Makoto Murata,21
Toshiki Uchida,22 Hiroatsu Iida,23 Kazuaki Yakushiji,24 Takuya Yamashita,25 Atsushi Wake,2
Satoshi Takahashi,26 Yoichi Takaue,1 Shuichi Taniguchi2To evaluate whether rescue with cord blood transplantation (CBT) could improve the poor survival after
graft failure (GF), we surveyed the data of 80 adult patients (median age, 51 years) who received CBTwithin
3 months of GF (primary 64, secondary 16), with fludarabine-based reduced-intensity regimens with or with-
out melphalan, busulfan, cyclophosphamide, and/or 2-4 Gy total-body irradiation (TBI). A median number of
2.4 107/kg total nucleated cells (TNC) were infused, and among the 61 evaluable patients who survived for
more than 28 days, 45 (74%) engrafted. The median follow-up of surviving patients was 325 days, and the
1-year overall survival rate was 33% despite poor performance status (2-4, 60%), carryover organ toxicities
(grade 3/4, 14%), and infections (82%) prior to CBT. Day 100 transplantation-related mortality was 45%, with
60% related to infectious complications. Multivariate analysis showed that the infusion of TNC$2.5 107/kg
and an alkylating agent–containing regimen were associated with a higher probability of engraftment, and that
high risk-status at the preceding transplantation and grade 3/4 organ toxicities before CBTwere associated
with an increased risk of mortality. In conclusion, in an older population of patients, our data support the
feasibility of CBTwith a reduced-intensity conditioning regimen for GF.
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transplantationINTRODUCTION
Graft failure or rejection (GF) is a serious problem
early after allogeneic stem cell transplantation (SCT)
using cord blood (CB) [1-6], an HLA-mismatched do-
nor [7], and nonmyeloablative or reduced-intensity
conditioning (RIC) regimens [8-13]. The incidence
of GF was low after SCT from an HLA-matched re-
lated (2%) [14] or unrelated donor (0.7%-1.7%)
[15,16]. In contrast, the incidence of GF was 14%-
22% for SCT from an HLA-mismatched unrelated
donor [15], 8%-20% for cord blood transplantation
(CBT) [17,18], and 5%-21% for SCT from an
unrelated donor using RIC [12,13]. The outcome of
GF becomes generally poor because of an increased
risk of infectious complications, which occur during
prolonged severe neutropenia with associated organ
toxicities. Whereas the survival rate after GF was 8%
when no rescue transplantation was performed [19],
the survival rate improved to 25%-40%when a second
transplantation was performed [19-22].
The treatment of GF generally depends on 2 major
basic mechanisms, that is, (1) poor graft function and (2)
immunologicallymediated graft rejection. Although the
boost infusion of CD341 stem cells, selected or unma-
nipulated, has been reported tobe effective in the former
case [23,24], in the latter case, retransplantation with
immunosuppressive conditioning is required for
effective reconstitution of hematopoiesis [21,25-27].
Nevertheless, transplantation-related mortality (TRM)
is still high because at the second SCT, most patients
have poor performance status (PS), organ toxicities, car-
ryover infection because of prolonged cytopenia, and
difficulties in finding a suitable donor on an emergency
basis. An additional problem is overlapping regimen-
related toxicity (RRT) because of the conditioning reg-
imen for the second SCT.
CBis a readily available stemcell source and,with the
current development of efficient banking systems, most
patients can readily find a suitableCBunit [28].Many re-
ports have shown the feasibility of reduced-intensity cord
blood transplantation (RICBT) in older patients and pa-
tients with comorbidities [29,30]. Additionally, small
case series of patients who were successfully rescued
with retransplantation using CB after GF have also
been reported [31-36]. Hence, CBT is a potential
target of clinical research for GF. Nevertheless, the
inevitable risks associated with CBT, that is, slower
neutrophil engraftment and resultant higher risk of GF
[17,18], may become critical barriers. To investigate
whether salvage therapy with RICBT is a feasible
therapeutic option for adult patients suffering fromGF, we conducted a nationwide survey of RICBT that
was performed as salvage therapy for GF.PATIENTS AND METHODS
Data Sources and Patient Selection
Questionnaires were sent to 131 transplant centers
in Japan, and 42 centers agreed to enroll consecutive
cases in this study. This study was approved by the
institutional review board of the National Cancer
Center. The inclusion criteria for this study were as
follows: (1) patients with hematologic disorders above
age 16 years who received allogeneic SCT between
January 2000 and April 2006, which resulted in pri-
mary or secondary GF, and (2) those who subsequently
received fludarabine-based RICBT as salvage therapy
within 3months of the diagnosis of GF. The definition
of a RIC regimen was according to the previous report
by Giralt [37]. Patients who had relapse or disease pro-
gression before rescue RICBT were not included.
The total number of allogeneic SCT performed
during this studyperiod in42 centerswas5622 including
related donors (n5 2556), unrelated donors (n5 1907)
and cord blood donors (n5 1159). Among 240 patients
who experienced GF, 146 underwent salvage SCT and
94 did not. The stem cell source was CB (n 5 102) or
non-CB (n 5 44). Among the 102 CBT recipients, 80
patients fulfilled the criteria for this study after excluding
12 patients who received myeloablative conditioning
and 10 patientswho received no toxic drug as condition-
ing regimen (antithymocyteglobulin [ATG]only, n5 5;
steroid only, n 5 3; total lymphoid irridiation [TLI]
only, n5 1; no conditioning, n5 1).
Definitions
Neutrophil engraftment was defined as the first of 3
consecutive days after transplantation that the absolute
neutrophil count (ANC) exceeded 500/mm3 of periph-
eral blood.PrimaryGFwasdefined according to aprevi-
ous report [15] as (1) failure of ANC to surpass 500/mm3
or (2) absence of donor T cells (\5%) before relapse,
disease progression, second SCT, or death. Secondary
GF was defined as (1) decrease in ANC\100/mm3 at
3 determinations or (2) absence of donor T cells
(\5%) after the initial engraftment without recovery
before relapse, disease progression, second SCT, or
death. Chimerism was assessed using fluorescent in
situ hybridization in sex-mismatched donor-recipient
pairs. In sex-matched pairs, polymerase chain reaction
(PCR) for short tandem repeats or variable numbers of
tandem repeats was used to detect donor cells at
Table 1. Patients and Tranaplantation Characteristics at the
First SCT
Parameters n 5 80*
Median age at first SCT (range) 51 years (17-68)
Male/female 34/46
Underlying diagnosis†
AML 43 (54%)
MDS 10 (13%)
ALL 13 (16%)
Other 14 (18%)
Disease risk‡
Standard risk 49 (61%)
High risk 31 (39%)
Preceding chemotherapy
Yes 66 (83%)
No§ 14 (17%)
Conditioningt
Myeloablative 37 (46%)
Reduced-intensity 43 (54%)
Donor and stem cell source
Related BM or PB 5 (6%)
Unrelated BM 16 (20%)
Unrelated CB 59 (74%)
Type of GF
Primary 64 (80%)
Secondary 16 (20%)
SCT indicates stem cell transplantation; AML, acute myeloid leukemia;
MDS, myelodysplastic syndrome; ALL, acute lymphoblastic leukemia;
BM, bone marrow; PB, peripheral blood; CB, cord blood; GF, graft
failure; RAEB, refractory anemia with excess blasts; CML, chronic
myelogeneous leukemia; CY, cyclophosphamide; TBI, total-body irradi-
ation; BU, busulfan.
*Before undergoing the SCT that resulted in GF, 6 patients had received
preceding transplantation.
†AML included overt AML evolved from MDS. MDS included RAEB-I or
II (n 5 9) and atypical CML (n 5 1). Other diagnoses included non-
Hodgkin lymphoma (n 5 6), aplastic anemia (n 5 5), and CML (n 5 3).
‡Standard risk included acute leukemia and non-Hodgkin lymphoma in
any complete remission, CML in any chronic phase, and aplastic anemia.
High risk included all other leukemia and non-Hodgkin lymphoma
categories, and MDS-RAEB.
§Forteen patients includedMDS (n5 7), AML (n5 2), or aplastic anemia
(n 5 5).
tMyeloablative conditionings included CY/TBI (n 5 27), BU/CY (n 5
6), and other TBI-based regimen (n 5 4). Reduced-intensity condition-
ings included fludarabine-based (n 5 37), cladribine-based (n 5 2), and
others (n 5 4) with (n 5 26) or without (n 5 17) 2-4 Gy TBI.
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lected, or marrow cells were assessed for chimerism at
the time of neutrophil engraftment depending on the
decision at each transplant center. HLA matching was
reported using serological typing of HLA-A and
HLA-B and allele typing of HLA-DRB1 of donor-re-
cipient pairs except for 5 patients. Standard risk was de-
fined as all complete remission of hematologic
malignancy, chronic phaseof chronicmyeloid leukemia,
or aplastic anemia. High risk was defined as other status
of hematologic malignancy and all myelodysplastic syn-
drome refractory anemia with excess blasts (MDS-
RAEB), including nonremission atypical CML. PS was
defined according to the ECOG criteria [39]. RRT
was evaluated by the Common Terminology Criteria
for Adverse Events version 3.0 (CTCAE v3.0) [40].
The diagnosis and clinical grading of acute graft-
versus-host disease (aGVHD) were based on the estab-
lished criteria [41]. Relapse was defined as an increase
of blastmore than5%inbonemarrowwithhematologic
malignancy.
First Transplant Procedures
Patients and transplantation characteristics at the
first SCT that resulted in subsequent GF are summa-
rized in Table 1. The median age of the 80 patients
was 51 years (range: 17-68). Disease risk before the
first SCT was standard risk in 49 patients (61%) and
high risk in 31 patients (39%). Donor source for the
first SCT included unrelated CB in 74% and unrelated
bone marrow (BM) in 20%. Because the JapanMarrow
Donor Program does not permit the donation of gran-
ulocyte colony-stimulating factor (G-CSF)-mobilized
peripheral blood stem cell (PBSC) from unrelated
donors, the stem cell source from unrelated donors
was BM or CB. GVHD prophylaxis varied among
the transplant centers.
After the first SCT, 64 patients experienced pri-
mary GF at a median of 28 days (range: 16-56 days),
and 16 patients experienced secondary GF at a median
of 36 days (range: 20-156). Data for chimerism analysis
were available in 65 patients (primary GF, n5 49; sec-
ondary GF, n 5 16). Among them, 45 patients had
\5%donor cells (primaryGF, n5 40, 82%; secondary
GF, n 5 5, 31%), which suggested immunologically
mediated graft rejection, and 20 patients had donor
cells ranging from 5% to 100% (primary GF, n 5 9,
18%; secondary GF, n 5 11, 69%), which suggested
poor graft function.
Second Rescue Transplant Procedures
Patients and transplantation characteristics at the
second SCT using RICBT as salvage therapy for GF
are summarized in Table 2. The median intervals
between the first SCT to the second SCT and the
diagnosis of GF to the second SCT were 47 days and15 days, respectively. Forty-eight patients (60%) had
poor PS at the second SCT, and 11 patients (14%)
had grade 3 or 4 carryover organ toxicities. Within 3
weeks of the start of conditioning for the second
SCT, 66 patients (82%) had documented infection
or febrile neutropenia that required intravenous anti-
biotics. More than half of the patients received a graft
with serologic 2- or 3-locusHLAmismatches.We also
examined the effect of HLA mismatch with serologic
HLA-A, B and allele DRB1 except for 5 patients whose
allele typing was not performed. The median body
weight of the recipients was 55 kg (range: 33-110),
and the median number of total nucleated cells
(TNC) was 2.4 107/kg recipient body weight (range:
1.03-4.3) at cryopreservation. All patients received
a fludrabine-containing reduced-intensity regimen
with or without 2-4 Gy TBI. As there are no
Table 2. Patients and Transplantation Characteristics at the
Second SCT (RICBT) for GF
Parameters n 5 80
Median time interval between
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the different conditioning regimens were chosen at the
discretion of the attending physicians. G-CSF was ad-
ministered in all but 1 patient after CBT.The first and second SCT 47 days (range: 27-203)
Diagnosis of GF and the second SCT 15 days (range: 4-61)
PS at the second SCT
0-1 32 (40%)
2-4 48 (60%)
Carryover organ toxicities at the
second SCT*
Grade 0-2 69 (86%)
Grade 3-4 11 (14%)
Carryover infection at the second SCT†
Documented 40 (50%)
Febrile neutropenia 26 (32%)
None 14 (18%)
The median TNC of CB 2.4  107/kg (range: 1.03-4.3)
Numbers of serological HLA mismatch
in GVH direction
0-1 32 (40%)
2-3 48 (60%)
HVG direction
0-1 33 (41%)
2-3 47 (59%)
Conditioning‡
Flu alone 20 (25%)
Flu + Mel 22 (28%)
Flu + Bu 18 (22%)
Flu + CY 17 (21%)
Flu + others 3 (4%)
with 2-4 Gy TBI 35 (44%)
without TBI 45 (56%)
GVHD prophylaxis§
CSP alone 17 (21%)
CSP + sMTX 6 (8%)
TAC alone 40 (50%)
TAC + sMTX 8 (10%)
Others 9 (11%)
SCT indicates stem cell transplantation; RICBT, reduced-intensity cord
blood transplantation; GF, graft failure; PS, performance status; TNC, to-
tal nucleated cells; CB, cord blood; HLA, human leukocyte antigen;
GVH, graft-versus-host; HVG, host-versus-graft; Flu, fludarabine; Mel,
melphalan; Bu, busulfan; CY, cyclophosphamide: TBI, total-body irradia-
tion; GVHD, graft-versus-host disease; CSP, cyclosporine; sMTX, short-
term methotrexate; TAC, tacrolimus.
*Grade of organ toxicities was evaluated by the CTCAE v3.0 [40].
Grade 3 toxicities included liver (n 5 5), lung (n 5 3), renal/bladder
(n 5 2), heart (n 5 1), stomatitis (n 5 1), and central nervus system
(n 5 1). Grade 4 toxicity included lung only (n 5 1).
†Documented infection included bacteremia (n 5 27), pneumonia (n 5
5), aspergillus infection (n5 3), subcutaneous abscess (n5 2), and others
(n 5 3).
‡The median total doses of each conditioning regimen were as follows:
Flu (138 mg/m2), Mel (80 mg/m2), Bu (8 mg/kg), and CY (60 mg/kg).
Antithymocyte globulin was also used in 8 patients (Flu alone [n 5 5],Statistical Analyses
The primary endpoint of this study was the engraft-
ment rate in patientswho survived formore than28 days
after salvage RICBT. The secondary endpoints were
TRM, overall survival (OS), and progression-free sur-
vival (PFS) from the day of salvage RICBT. For calcula-
tion of PFS, 5 patients with aplastic anemia were
excluded from the analysis. OS and PFS were estimated
using the Kaplan-Meier method. The cumulative inci-
dences of engraftment and TRM were evaluated using
Gray’s method, considering death without engraftment
and relapse, respectively, as competing risks. The log-
rank test and the generalized Wilcoxon test were used
to compare the probabilities of OS, PFS, TRM, and
relapse after the second transplantation over time across
patient subgroups.
Factors associated with at least borderline signifi-
cance (P\ .10) in the univariate analyses were sub-
jected to a multivariate analysis using backward
stepwise proportional-hazard modeling. Finally,
P values of\.05 were considered statistically signifi-
cant. Clinical factors that were assessed for their asso-
ciation with engraftment rate, TRM, and OS included
sex, patient age at the time of the first SCT (\50 years
versus $50 years), disease risk at the first SCT (stan-
dard risk versus high risk), conditioning for the first
SCT (myeloablative versus reduced-intensity), PS at
the second SCT (0-1 versus 2-4), carryover organ
toxicities at the second SCT (grade 0-2 versus 3-4),
carryover infection at the second SCT (documented
versus febrile neutropenia/none), conditioning regi-
mens for the second SCT (containing alkylating agents
versus others), including TBI at the second SCT (non-
TBI versus TBI 2-4 Gy), use of MTX (yes versus no),
TNC (\2.5 versus $2.5  107/kg), and numbers of
HLA mismatches in the graft-versus-host direction
(0-1 versus 2-3) and host-versus-graft direction (0-1
versus 2-3). The statistical analysis was performed
with SAS ver.8 (SAS Institute, Cary, NC).Flu + Mel [n 5 1], and Flu + Bu [n 5 2]). Other conditioning regimens
included Flu plus thiotepa (n5 2) or etoposide (n5 1). Twelve patients
received 2 Gy TBI and 23 patients received 4 Gy TBI.
§Other prophylaxis includedCSP/TACplusmycophenolatemofetil (n57)
or prednisolone (n5 2).RESULTS
Neutrophil and Platelet Engraftment (Table 3)
The cumulative incidences of neutrophil engraft-
ment and death without engraftment are shown in
Figure 1A. Among 61 patients who survived for more
than 28 days after the second SCT, 45 (74%) achieved
neutrophil engraftment at a median of 21 days (range:
13-44) (Table 3). The other 33 patients failed to
achieve engraftment because of early TRM within 28days after RICBT (n 5 17), early relapse (n 5 3) at
days 22-25, or primary GF (n 5 13). The remaining
2 patients died of TRM within 28 days after obtaining
neutrophil engraftment. Among 13 patients who expe-
rienced primary GF after second SCT, chimerism
analyses were performed in 4 patients to confirm the
diagnosis of GF at a median of 25 days (range: 21-28).
Figure 1. Cumulative incidence of neutrophil engraftment. (A) The
cumulative incidences of neutrophil engraftment (solid line) and death
without engraftment (dotted line) are shown. (B) The cumulative
incidence of neutrophil engraftment was higher in patients who received
alkylating agent–containing regimen (solid line) than in those who did
not (dotted line) (P5.0001). (C) The cumulative incidence of neutrophil
engraftment was higher in patients who received graft containing TNC
$2.5  107/kg than in those who did not (P 5 .01).
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higher in patients who received alkylating agents in-
cluding melphalan, busulfan, and cyclophosphamide
as part of conditioning for the second SCT (73%
versus 26%, P 5 .0001), as shown in Figure 1B. The
engraftment rate was similar among the 3 types ofconditioning regimens that included alkylating agents.
The incidence of neutrophil engraftment was higher
when patients received 2-4 Gy TBI (71% versus
50%, P5 .03). The engraftment rate was higher in pa-
tients who received graft containing a higher number
of TNC $2.5  107/kg than in those who received
\2.5  107/kg (73% versus 50%, P 5 .01)
(Figure 1C). When 2.0  107/kg was used as a cutoff
for TNC, the engraftment rate tended to be higher
in patients who received graft that contained higher
TNC (65% versus 36%, P 5 .08). The standard-risk
group at the first SCTwas also associated with a higher
neutrophil engraftment than the high-risk group (70%
versus 43%, P5 .02). The number of CD341 cells was
evaluated in 68 patients with a median of 0.6  105/kg
(range: 0.1-4.22), and this was not associated with the
neutrophil engraftment rate. In 14 patients who re-
ceived MTX for GVHD prophylaxis after the second
SCT, neutrophil engraftment was delayed (median
31 days; range: 14-44 days) compared to those who
did not receive MTX (median 21 days; range: 13-42
days), although the ultimate engraftment rates were
similar (50% versus 61%, P 5 .26). In 8 patients who
received ATG for the second SCT, 3 (38%) achieved
neutrophil engraftment. Anti-HLA antibody was
examined before the second SCT in 28 patients. In 9
patients with positive anti-HLA antibody, only 2
(22%) achieved engraftment and 6 (67%) died within
28 days after RICBT. Among 47 patients who ob-
tained neutrophil engraftment, with chimerism analy-
ses available in 44 patients at a median of 30 days
(range: 12-119), 42 patients (95%) achieved complete
donor chimerism, and 2 continued to show mixed chi-
merism. Among 61 patients who survived for more
than 28 days, 31 patients (51%) achieved platelet
engraftment that wasmore than 20,000/mL, and subse-
quently 27 patients (44%) obtained platelet engraft-
ment more than 50,000/mL. The median day of last
platelet transfusion was 53 days (range: 15-197) after
the second SCT.RRTand aGVHD (Table 3)
Grade 3 or 4 RRT excluding febrile neutropenia
was recognized in 48 patients (60%) after the second
SCT, which included toxicities associated with stoma-
titis (n 5 8), liver damage (n 5 20), diarrhea (n 5 11),
renal and bladder (n5 10), heart (n5 8), lung (n5 21),
and central nervous system (CNS) (n 5 18). The
details of CNS complication were limbic encephalitis
including HHV-6 encephalitis (n 5 8), brain hemor-
rhage (n5 3), cerebral aspergillosis (n5 2), and others
(n 5 5). TRM was 75% in 48 patients who developed
grade 3 or 4 organ toxicities, and 28% in the remaining
32 patients without grade 3 or 4 organ toxicities after
the second SCT. The probabilities of grades II-IV
and III-IV aGVHD were 25% and 11%, respectively,
Table 3. Outcomes after the Second SCT (RICBT)
Parameters n 5 80
The engraftment rate in 61 patients
surviving >28 days
45 (74%)
GF in 61 patients surviving >28 days 13 (21%)
Grade 3-4 organ toxicities* 48 (60%)
Documented infection 58 (63%)
CMV antigenemia 36 (45%)
Acute GVHD
Grade II-IV 20 (25%)
Grade III-IV 9 (11%)
Relapse 12 (15%)
Death 51 (64%)
The median day of death after
second SCT
37 days (range: 2-611)
Causes of death
Infection 33 (65%)
Bacterial 14
Fungal 6
Viral 8
Complex or unknown 5
Relapse 6 (12%)
Acute GVHD 1 (2%)
Other† 11 (22%)
SCT indicates stem cell transplantation; RICBT, reduced-intensity cord
blood transplantation; GF, graft failure; CMV, cytomegalovirus; GVHD,
graft-versus-host disease.
*Grade of organ toxicities was evaluated by the CTCAE v3.0 [40].
†Other causes included cerebral hemorrhage (n5 3), multiorgan failure
(n5 2), thrombotic microangiopathy (n5 2), veno-occulusive disease of
the liver (n 5 1), interstitial pneumonitis (n 5 1), heart failure (n 5 1),
and secondary malignancy (n 5 1). Figure 2. Cumulative incidence of transplantation-related mortality
(TRM) and relapse. (A) The cumulative incidences of TRM (solid line)
and relapse (dotted line) are shown. (B) The cumulative incidence of
TRM was higher in patients who had grade 3 or 4 carryover organ
toxicity before the second SCT (solid line) than in those who did not
(dotted line) (P 5 .03).
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GVHD.TRM, Relapse, and Causes of Death (Table 3)
Fifty-one patients (64%) died at a median of 37
days (range: 2-611) after the second SCT. The cumu-
lative incidence of TRM was 45%, 56%, and 61% at
day 100, 1 year, and 2 years, respectively (Figure 2A),
and infection was the most frequent cause of death.
Notably, death that was directly related to bacterial in-
fection occurred during prolonged neutropenia in the
first 2 months after the second SCT. In 11 patients
with grade 3 or 4 carryover organ toxicities at the sec-
ond SCT, 8 (73%) died of TRM (Figure 2B). TRM
was higher in patients who received an oral busulfan-
based regimen (72%) than in those who received
melphalan-based (50%) or cyclophosphamide-based
(53%) regimens. Underlying malignancy relapsed in
12 patients (16%) at a median of 158 days (range:
22-781) after the second SCT, and 3 patients received
a third SCT after relapse. Overall, 6 patients died of
disease recurrence.Survival
The median follow-up time in the surviving pa-
tients was 325 days (range: 89-1069) after the second
SCT. The Kaplan-Meier curves of OS and PFS of all
80 patients are shown in Figure 3A. The estimatedrates of OS and PFS at 1 year after the second SCT
were 33% and 29%, respectively. The OS was worse
in 11 patients who had grade 3 or 4 carryover organ
toxicities at the second SCT compared to the other
69 patients. OS was significantly better in patients
who had standard-risk disease at the first SCT than
in those who had high-risk disease (Figure 3B).Factors Associated with Engraftment and OS
In a univariate analysis, standard risk at the first
SCT, PS 0-1 at the second SCT, conditioning that in-
cluded alkylating agents or 2-4 Gy TBI, and a higher
dose of infusedTNC ($2.5 107/kg)were significantly
associated with a higher probability of engraftment.
Carryover organ toxicities (P 5 .09) and infection at
the second SCT (P5 .07) were also included in amulti-
variate analysis. The type of engraftment failure after
first SCT did not have an influence on outcome after
the second SCT (primary versus secondary). As a result,
higher TNC dose ($2.5 107/kg: hazard ratio [HR]5
2.14, 95%confidence interval [CI], 1.29-3.52;P5 .003),
conditioning that included alkylating agents (HR 5
3.70, 95% CI, 1.51-9.09; P 5 .005), and standard risk
at first SCT (HR 5 2.04, 95% CI, 1.06-3.85; P 5 .03)
Figure 3. OS and PFS. (A) The Kaplan-Meier estimates of OS (solid
line) and PFS (dotted line) are shown. (B) OS in patients who were
high risk at the first SCT (dotted line) was lower than that in those
who were standard risk (solid line) (P 5 .003).
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tional hazards regression analysis (Table 4). In a multi-
variate Cox proportional hazards regression analysis of
OS, high-risk disease at the first SCT (HR 5 2.14,
95% CI, 1.20-3.81; P 5 .01) and grade 3 or 4 carry-
over organ toxicities at the second SCT (HR 5 2.84,
95%CI, 1.33-6.06;P5 .007)were associatedwith an in-
creased risk of poor OS (Table 5).DISCUSSION
Based on data obtained from this large cohort of
patients, we showed that neutrophil engraftment can
be achieved in .70% of adult patients who received
RICBT as salvage therapy for GF. Although our cohort
was composed of rather older patients, the engraftment
rate was comparable to that reported in primary CBT
[17,18,29,34]. Considering the poor PS and carryover
infection and organ toxicities, salvage therapy with
RICBT is a feasible option that gave a 1-year OS of
33%. Nevertheless, this procedure is still associated
with a high rate of TRM (45% at day 100), 60% of
which was related to infectious complications, and we
performed analyses to identify the risk factors for
engraftment and survival.Guardiola et al. [22] reported in 82 patients with
various hematological diseases who underwent second
allogeneic SCT that the neutrophil engraftment rate
and 3-year OS were 70% and 30%, respectively.
They showed that a longer intertransplant interval of
$80 days was associated with a higher neutrophil en-
graftment rate and survival in a multivariate analysis.
McCann et al. [19] also reported that a longer interval
of $60 days was associated with a higher engraftment
rate and OS in 41 patients with aplastic anemia. In our
study, we did not find any association between interval
and neutrophil engraftment or OS, and this discrep-
ancy may be because of differences in the cohorts of
patients evaluated. In the report by Guardiola et al.
[22], the proportions of patients who experienced
secondary GF and who received transplant from an
HLA-matched sibling donor were much higher than
in our study (66% versus 20%, 78% versus 6%, respec-
tively). Grandage et al. [25] reported successful en-
graftment in 12 patients who underwent a second
SCT from the same unrelated donor after GF. In the
current study, however, it was not possible to perform
a second SCT using an unrelated BM donor because
most patients had poor PS, organ toxicities, or infec-
tions with prolonged cytopenia (ANC\100/mm3).
Our data confirmed that a higher number of in-
fused CB cells (TNC $2.5  107/kg) was associated
with a higher probability of neutrophil engraftment af-
ter the second RICBT (P5 .01), which was consistent
with previous reports [4,42]. Because the median body
weight of patients in this study was 55 kg, CB units
containing .2.0  107/kg were available in .80% of
patients. A double cord blood unit strategy might be
favorable as previous reported, because a higher cell
dose was associated with better survival [43]. Although
in a previous study by Wagner et al. [44], the total
number of CD341 cells was reported to be a major
determinant of neutrophil recovery after CBT, our
present findings did not confirm this point. Another
discrepancy with previous reports [44] is that HLA dis-
parity between the donor and recipient was not related
to the engraftment rate in our study.We also examined
the effect of HLA mismatch with serological HLA-A,
B and allele DRB1 except for 5 patients whose allele
typing was not performed. However, the results
remained unchanged, and there was no impact on
engraftment and OS.
The need for an intensive immunosuppressive
conditioning regimen before the second SCT for GF
depends on the mechanism of GF, and we found
that a fludarabine-based regimen that included alkylat-
ing agents was associated with a higher neutrophil
engraftment rate. Whereas the use of cytotoxic drugs
is not mandatory before stem cell boost for patients
who have poor graft function [23,24], intensive
immunosuppressive conditioning is essential to
suppress residual host T and natural killer cells to
Table 4. Univariate and Multivariate Analysis of Factors Predicting Engraftment after the Second SCT
Univariate Multivariate
Covariates Proportion (%)* P Hazard Ratio (95% CI) P
Disease risk at the first SCT† .02 .03
Standard risk 70 2.04 (1.06-3.85)
High risk 43 1.00
Type of graft failure .57 —
Primary 58 —
Secondary 56 —
Interval between the first SCT and second SCT .87 —
<50 days 60 —
$50 days 59 —
PS .01 —
0-1 81 —
2-4 46 —
Carryover organ toxicities at the second SCT‡ .09 —
Grade 0-2 65 —
Grade 3-4 27 —
Carryover infection at the second SCT .07 —
Febrile neutropenia/none 69 —
Documented infection 51 —
Conditioning§ .0001 .005
Alkylating agent–containing 73 3.70 (1.51-9.09)
Other 26 1.00
TBI .03 —
2-4 Gy TBI 71 —
No TBI 50 —
TNC of the CB .01 .003
$2.5  107/kg 73 2.14 (1.29-3.52)
<2.5  107/kg 50 1.00
SCT indicates stem cell transplantation; PS, performance status; TBI, total-body irradiation; TNC, total nucleated cells; CB, cord blood; GVHD, graft-
versus-host disease; HLA, human leukocyte antigen; CML, chronic myelogeneous leukemia; MDS, myelodysplatic syndrome; RAEB, refractory anemia
with excess blasts; CI, confidence interval.
Other covariates examined included sex, patient age, conditioning of the first SCT, use of methotrexate as GVHD prophylaxis, and numbers of selorogic
HLA mismatch in graft-versus-host and host-versus-graft directions.
*Proportions of patients who achieved neutrophil engraftment.
†Standard risk included acute leukemia and non-Hodgkin lymphoma in any complete remission, CML in any chronic phase, and aplastic anemia. High risk
included all other types of leukemia and non-Hodgkin lymphoma categories, and MDS-RAEB.
‡Grade of organ toxicities was evaluated by the CTCAE v3.0 [40].
§Alkylating agents included melphalan, busulfan, and cyclophosphamide. Other conditioning included fludarabine alone and a combination of fludarabine
plus thiotepa or etoposide.
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previously reported in patients with aplastic anemia
[19,46], the addition of 2-4 Gy TBI to the RIC
regimen increased the probability of engraftment in
a univariate analysis, although it did not have
a significant effect in a multivariate analysis. In our
preliminary data, 6 of the 10 patients who received
second CBT without cytotoxic conditioning regimen
(ie, ATG only, steroid only, etc.) experienced GF
again after second SCT. Whereas the addition of
alkylating agent and low-dose TBI to the conditioning
regimen for the second RICBT enhanced neutrophil
engraftment, it did not affect the overall outcomes in
our study. To determine the best conditioning regi-
men for salvage RICBT after GF, further studies to
evaluate regimens including fludarabine plus melpha-
lan or cyclophosphamide with or without 2-4 Gy
TBI will be required.
In our study, the TRM early after the second
RICBTwas extremelyhigh (45%atday100),mainly be-
cause of infectious complications, which was consistent
with previous reports on CBT [5,17,29,30,47]. Thisis probably because of a prolonged period of severe
neutropenia before and after the second RICBT in
patients complicated with GF, which incubated
carryover infections. To reduce the incidence of
infection-relatedTRM, frequentmonitoring and exten-
sive treatment including granulocyte transfusion to
support the intertransplant period may be needed [48].
Alternatively, the earlier application of RICBT while
patients are still in better condition without infection
may be preferred to reduce TRM.
When patients require a second SCT for GF, the
selection of the donor source is critical. Based on the
feasibility of second RICBT in our study, we suggest
thatCB carries the highest priority for selection because
of its ready availability. Although the possibility of a sec-
ond SCT or boost of stem cells from the same related
donor of the first SCT has been reported [19,22], 75%
of our patients had undergone CBT at the first
transplant, which reflects the difficulty of finding
a suitable donor. Another possibility is a second SCT
from a haploidentical related donor [49,50]. The more
rapid neutrophil engraftment after SCT using PBSC
Table 5. Univariate and Multivariate Analysis of Overall Survival after the Second SCT
Univariate Multivariate
Covariates Proportion at 1 Year (%) P Hazard Ratio (95% CI) P
Disease risk at the first SCT* .03 .01
Standard risk 50 1.00
High risk 26 2.14 (1.20-3.81)
Type of graft failure .87 —
Primary 36 —
Secondary 39 —
Interval between the first SCT and second SCT .38 —
<50 days 40 —
$50 days 31 —
PS .2 —
0-1 39 —
2-4 35 —
Carryover organ toxicities at the second SCT† .001 .007
Grade 0-2 41 1.00
Grade 3-4 0 2.84 (1.33-6.06)
Carryover infection at the second SCT .14 —
Febrile neutropenia/none 46 —
Documented infection 27 —
Conditioning‡ .69 —
Alkylating agent–containing 35 —
Other 40 —
TBI .56 —
2-4 Gy TBI 37 —
No TBI 37 —
TNC of the CB .77 —
$2.5  107/kg 41 —
<2.5  107/kg 33 —
SCT indicates stem cell transplantation; PS, performance status; TBI, total-body irradiation; TNC, total nucleate cells; CB, cord blood; GVHD, graft-
versus-host disease; HLA. human leukocyte antigen; CML, chronic myelogeneous leukemia; MDS, myelodysplatic syndrome; RAEB, refractory anemia
with excess blasts; CI, confidence interval.
Other covariates examined included sex, patient age, conditioning of the first SCT, use of methotrexate as GVHD prophylaxis, and numbers of sero-
logical HLA mismatch in graft-versus-host and host-versus-graft directions.
*Standard risk included acute leukemia and non-Hodgkin lymphoma in any complete remission, CML in any chronic phase, and aplastic anemia. High risk
included all other types of leukemia and non-Hodgkin lymphoma categories, and MDS-RAEB.
†Grade of organ toxicities was evaluated by the CTCAE v3.0. [40].
‡Alkylating agents included melphalan, busulfan, and cyclophosphamide. Other conditioning included fludarabine alone and a conbination of fludarabine
plus thiotepa or etoposide.
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infectious complications in patients suffering from GF.
However, compared to CBT, the feasibility of this
procedure has not yet been established and the
incidence of acute GVHD increases. In addition,
collection of autologous stem cells prior to CBT
might be an option to salvage a fraction of patients
who experiencedGFas previously reported [51].Never-
theless, further studies are warranted to determine
which types of transplant, CBT or SCT from a haploi-
dentical related donor, can achieve better outcomes for
patients suffering from GF.
This study has several inherent limitations. First,
the patients and transplantation characteristics includ-
ing the conditioning regimen, GVHD prophylaxis,
and supportive care varied among the different centers.
Second, the timing of and general conditions at the
second RICBT differed among patients. Third, there
may be unrecognized biases because only successful
cases may have been collected. Finally, the duration
of follow-up for patients in this study was too short
to draw any definite conclusions. Nevertheless, thelarge cohort of 80 patients who received RICBT as sal-
vage therapy for GF in the current study allowed us to
make several clinically relevant observations.
In conclusion, we suggest that salvage therapy with
a second RICBT is a feasible therapeutic option for
patients who are suffering from GF. To achieve stable
neutrophil engraftment after the second RICBT, con-
ditioning with fludarabine plus alkylating agents and
the infusion of CB containing $2.5  107/kg cells
are preferable. A high TRM early after RICBT em-
phasizes the need for the earlier application of RICBT
while patients still have better PS and have not yet ac-
quired infection and organ toxicity. Prospective trials
are needed to determine the ultimate utility of rescue
RICBT using a fludarabine-based regimen including
alkylating agents for patients suffering from GF.ACKNOWLEDGMENTS
We thank the physicians in the participating cen-
ters who contributed to this survey. We also thank
850 Biol Blood Marrow Transplant 17:841-851, 2011F. Waki et al.Yukiko Iisaka and Mihoko Kanazawa for their assis-
tance with data collection, and Shin-ichiro Mori,
Sung-Won Kim, Ryuji Tanosaki, Dai Maruyama,
and Kensei Tobinai for their helpful discussions.
This work was supported in part by grants from the
Ministry of Health, Labor and Welfare, Japan. This
article was presented in part as a poster presentation
at the 48th Annual Meeting of the American Society
of Hematology, Orlando, FL, USA, December 2006.
Financial disclosure:The authors have no conflicting
financial interests to declare.AUTHORSHIP STATEMENT
F. Waki and T. Fukuda played a major role in
designing and performing the research, verifying the in-
tegrity of and analyzing the data, and writing the manu-
script. Y. Kanda played a major role in the statistical
analyses and in developing the concept of the research.
K. Masuoka, T. Yamashita, A. Wake, and S. Takahashi
designed the research and contributed vital data to
generate the final database. Y. Takaue and S. Taniguchi
designed the research andcontributed towritingor inter-
preting relevant parts of the manuscript. All other coau-
thors contributed vital data to generate the final database
and interpreted relevant parts of the manuscript.REFERENCES
1. Gluckman E, Broxmeyer HA, Auerbach AD, et al. Hematopoi-
etic reconstitution in a patient with Fanconi’s anemia by means
of umbilical-cord blood from anHLA-identical sibling.NEngl J
Med. 1989;321:1174-1178.
2. Wagner JE, Rosenthal J, Sweetman R, et al. Successful trans-
plantation of HLA-matched and HLA-mismatched umbilical
cord blood from unrelated donors: analysis of engraftment and
acute graft versus host disease. Blood. 1996;88:795-802.
3. Rubinstein P, Carrier C, Scaradavou A, et al. Outcomes among
562 patients of placental-blood transplants from unrelated
donors. N Engl J Med. 1998;339:1565-1577.
4. Laughlin MJ, Barker J, Bambach B, et al. Hematopoietic en-
graftment and survival in adult recipients of umbilical-cord
blood form unrelated-donors. N Engl J Med. 2001;344:
1815-1822.
5. Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after
transplantation of cord blood or bone marrow from unrelated
donors in adults with leukemia. N Engl J Med. 2004;351:
2265-2275.
6. Schoemans H, Theunissen K, Maertens J, et al. Adult umbilical
cord blood transplantation: a comprehensive review. Bone Mar-
row Transplant. 2006;38:83-93.
7. Aversa F, Terenzi A, Tabilio A, et al. Full haplotype-
mismatched hematopoietic stem-cell transplantation: a phase
II study in patients with acute leukemia at high risk of relapse.
J Clin Oncol. 2005;23:3447-3454.
8. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic
hematopoietic progenitor cells with purine analog-containing
chemotherapy: harnessing graft-versus-leukemia without mye-
loablative therapy. Blood. 1997;89:4531-4536.
9. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem
cell transplantation and cell therapy as an alternative to conven-
tional bone marrow transplantation with lethal cytoreductionfor the treatment of malignant and nonmalignant hematologic
diseases. Blood. 1998;91:756-763.
10. Childs R, Clave E, ContentinN, et al. Engraftment kinetics after
nonmyeloablative allogeneic peripheral blood stem cell trans-
plantation: full donor T-cell chimerism precedes alloimmune
responses. Blood. 1999;94:3234-3241.
11. McSweeney PA, Neiserwieser D, Shizuru JA, et al. Hematopoi-
etic cell transplantation in older patients with hematologic
malignancies: replacing high-dose cytotoxic therapy with graft-
versus-tumor effects. Blood. 2001;97:3390-3400.
12. Maris MB, Niederwieser D, Sandmaier BM, et al. HLA-
matched unrelated donor hematopoietic cell transplantation
after nonmyeloablative conditioning for patients with hemato-
logic malignancies. Blood. 2003;102:2021-2030.
13. Shaw BE, Russell NH, Devereux S, et al. The impact of donor
factors on primary non-engraftment in recipients of reduced
intensity conditioned transplants from unrelated donors.
Haematologica. 2005;90:1562-1569.
14. Anasetti C, Amos D, Beatty PG, et al. Effect of HLA compati-
bility on engraftment of bonemarrow transplantation in patients
with leukemia or lymphoma. N Engl J Med. 1989;320:197-204.
15. Petersdorf EW,Hansen JA, Martin PJ, et al. Major-histocompat-
ibility-complex class I alleles and antigens in hematopoietic-cell
transplantation. N Engl J Med. 2001;345:1794-1800.
16. Morishima Y, Sasazuki T, Inoko H, et al. The clinical signifi-
cance of human leukocyte antigen (HLA) allele compatibility
in patients receiving a marrow transplant from serologically
HLA-A, HLA-B, and HLA-DR matched unrelated donors.
Blood. 2002;99:4200-4206.
17. Rocha V, Labopin M, Sanz G, et al. Transplants of umbilical-
cord blood or bone marrow from unrelated donors in adults
with acute leukemia. N Engl J Med. 2004;351:2276-2285.
18. Takahashi S, Iseki T, Ooi J, et al. Single-institute comparative
analysis of unrelated bone marrow transplantation and cord
blood transplantation for adult patients with hematologic malig-
nancies. Blood. 2004;104:3813-3820.
19. McCann SR, Bacigalupo A, Gluckman E, et al. Graft rejection
and second bone marrow transplants for acquired aplastic
anaemia: a report from the aplastic anaemia working party of
the European bone marrow transplant group. Bone Marrow
Transplant. 1994;13:233-237.
20. Davies SM, Weisdorf DJ, Haake RJ, et al. Second infusion of
bone marrow for treatment of graft failure after allogeneic bone
marrow transplantation. Bone Marrow Transplant. 1994;14:73-77.
21. Storb R, Weiden PL, Sullivan KM, et al. Second marrow trans-
plants in patients with aplastic anemia rejecting the first graft:
use of a conditioning regimen including cyclophosphamide
and antithymocyte globulin. Blood. 1987;70:116-121.
22. Guardiola P, KuentzM, Garban F, et al. Second early allogeneic
stem cell transplantation for graft failure in acute leukaemia,
chronic myeloid leukaemia and aplastic anaemia. Br J Haematol.
2000;111:292-302.
23. Remberger M, Ringden O, Ljungman P, et al. Booster marrow
or blood cell for graft failure after allogeneic bone marrow
transplantation. Bone Marrow Transplant. 1998;22:73-78.
24. Larocca A, Piaggio G, Podesta M, et al. A boost of CD341-
selected peripheral blood cells without further conditioning in
patients with poor graft function following allogeneic stem cell
transplantation. Haematologica. 2006;91:935-940.
25. Grandage VL, Cornish JM, Pamphilon DH, et al. Second allo-
geneic bone marrow transplants from unrelated donors for graft
failure following initial unrelated donor bone marrow. Bone
Marrow Transplant. 1998;21:687-690.
26. Kernan NA, Bordignon C, Heller G, et al. Graft failure after
T-cell-depleted human leukocyte antigen identical marrow
transplants for leukemia: I. Analysis of risk factors and results
of secondary transplants. Blood. 1989;74:2227-2236.
27. Wolff SN. Second hematopoietic stem cell transplantation for
the treatment of graft failure, graft rejection or relapse after al-
logeneic transplantation. Bone Marrow Transplant. 2002;29:
545-552.
Biol Blood Marrow Transplant 17:841-851, 2011 851Feasibility of Salvage RICBTafter Graft Failure28. Barker JN, Krepski TP, DeFor TE, et al. Searching for unre-
lated donor hematopoietic stem cells: availability and speed of
umbilical cord blood versus bone marrow. Biol Blood Marrow
Transplant. 2002;8:257-260.
29. Barker JN, Weisdorf DJ, DeFor TE, et al. Rapid and complete
chimerism in adult recipients of unrelated donor umbilical cord
blood transplantation after reduced-intensity conditioning.
Blood. 2003;102:1915-1919.
30. Miyakoshi S, Yuji K, KamiM, et al. Successful engraftment after
reduced-intensity umbilical cord blood with advanced hemato-
logical diseases. Clin Cancer Res. 2004;10:3586-3592.
31. Khorshid O, deMeis E,Marin T, et al. Unrelated umbilical cord
blood stem cell transplant after failure of haploidentical or
matched unrelated donor hematopoietic stem cell transplant.
Leukemia. 2003;17:2538-2540.
32. Ohwada C, Nakaseko C, Ozawa S, et al. Second cord blood
transplantation (CBT) with reduced-intensity conditioning for
graft failure after the first CBT for AML. Bone Marrow Trans-
plantat. 2004;34:999-1000.
33. Tomonari A, Takahashi S, Shimohakamada Y, et al. Unrelated
cord blood transplantation for a human immunodeficiency
virus-1-seropositive patient with acute lymphoblastic leukemia.
Bone Marrow Transplant. 2005;36:261-262.
34. Narimatsu H, Kami M, Miyakoshi S, et al. Graft failure follow-
ing reduced-intensity cord blood transplantation for adult pa-
tients. Br J Haematol. 2006;132:36-41.
35. Shimada K, Narimatsu H, Morishita Y, et al. Severe regimen-
related toxicityof second transplantation forgraft failure following
reduced-intensity cord blood transplantation in an adult patient.
Bone Marrow Transplant. 2006;37:787-788.
36. Kawamori Y, Yakushijin K, Okamura A, et al. Successful en-
graftment in reduced-intensity cord blood transplantation
(CBT) as a salvage therapy for graft failure after primary CBT
in adults. Transplantation. 2007;83:1281-1282.
37. Giralt S. Reduced-intensity conditioning regimen for hemato-
logic malignancies: what have we learned over the last 10 years?
Hematology. 2005;384-389.
38. Thiede C, BornhauserM, Ehuinger G. Chimerism diagnosis af-
ter allogeneic hematopoietic stem cell transplantation.Acta Hae-
matol. 2004;112:16-23.
39. Oken MM, Creech RH, Tormey DC, et al. Toxicity and
response criteria of the Eastern Cooperative Oncology Group.
Am J Clin Oncol. 1982;5:649-655.
40. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: develop-
ment of a comprehensive grading system for the adverse effects
of cancer treatment. Semin Radiat Oncol. 2003;13:176-181.
41. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus
conference on acute GVHD grading. Bone Marrow Transplant.
1995;15:825-828.
42. Barker JN, Scaradavou A, Stevens CE, Rubinstein P. Analysis of
608 umbilical cord blood (UCB) transplants: HLA-match is
a critical determinant of transplant-related mortality (TRM) in
the post-engraftment period even in the absence of acute
graft-vs-host disease (aGVHD). Blood. 2005;106:92a-93a
(Abstract 303).
43. Barker JN, Weisdorf DJ, DeFor TE, et al. Transplantation of 2
partially HLA-matched umbilical cord blood units to enhance
engraftment in adults with hematologic malignancy. Blood.
2005;105:1343-1347.
44. Wagner JE, Barker JN, DeFor TE, et al. Transplantation of
unrelated donor umbilical cord blood in 102 patients with
malignant and nonmalignant disease: influence of CD34 cell
dose and HLA disparity on treatment-related mortality and sur-
vival. Blood. 2002;100:1611-1618.
45. Murphy WJ, Koh CY, Raxiuddin A, Bennett M, Longo DL.
Immunobiology of natural killer cells and bone marrow trans-
plantation: merging of basic and preclinical studies. Immunol
Rev. 2001;181:279-289.46. Deeg HJ, Amylon MD, Harris RE, et al. Marrow transplants
from unrelated donors for patients with aplastic anemia: mini-
mum effective dose of total body irradiation. Biol Blood Marrow
Transplanat. 2001;7:208-215.
47. Narimatsu H, Matsumura T, Kami M, et al. Bloodstream infec-
tion after umbilical cord blood transplantation using reduced-
intensity stem cell transplantation for adult patients. Biol Blood
Marrow Transplant. 2005;11:429-436.
48. Bishton M, Chopra R. The role of granulocyte transfusions in
neutropenic patients. Br J Haematol. 2004;127:501-508.
49. Tanaka T, Matsubara H, Adachi S, et al. Second transplantation
from HLA 2-loci-mismatched mother for graft failure because
of hemophagocytic syndrome after cord blood transplantation.
Int J Hematol. 2004;80:467-469.
50. Lang P,Muller I, Greil J, et al. Retransplantation with stem cells
frommismatched related donors after graft rejection in pediatric
patients. Blood Cells Mol Dis. 2008;40:33-39.
51. Rondon G, Saliba RM, Khouri I, et al. Long-term follow-up of
patinets who experienced graft failure postallogeneic progenitor
cell transplantation. Results of a single institution analysis. Biol
Blood Marrow Transplant. 2008;14:859-866.APPENDIX
The following institutions contributed data to this
study: Kei Fukuhara, Department of InternalMedicine,
AsahikawaCityHospital, Asahikawa;TatsuoFurukawa,
Division of Hematology, Niigata University Graduate
School of Medicine, Niigata; Yasuo Tohmiya, Depart-
ment of Internal Medicine, Miyagi Cancer Center,
Sendai; Tatsuyuki Kai, Department of Hematology,
Kita-Fukushima Medical Center, Fukushima; Toru
Sakura, Department of Internal Medicine, Saiseikai
Maebashi Hospital, Maebashi; Naoki Takahashi, Divi-
sion of Hematology, Department of Internal Medicine,
Saitama Medical University, Saitama; Miki Nishimura,
Department of Hematology, Chiba University Gradu-
ate School of Medicine, Chiba; Kenji Tajika, Third
Department of Internal Medicine, Nippon Medical
School, Tokyo; Shin Fujisawa, Department of Hema-
tology, Yokohama City University Medical Center,
Yokohama; Tadashi Koike, Department of Hematol-
ogy, Nagaoka Red Cross Hospital, Nagaoka; Akiyoshi
Takami, Department of Cellular Transplantation Biol-
ogy, Kanazawa University Graduate School of Medical
Science, Kanazawa; Morishita Yoshihisa, Division of
Hematology, JAAichi SyowaHospital,Kohnan;Tatsuo
Ichinohe, Department of Hematology/Oncology,
Kyoto University Hospital, Kyoto; Jun Ishikawa, De-
partment of Hematology and Oncology, Graduate
School of Medicine, Osaka University, Osaka; Mitsuru
Tsudo, Department of Hematology, Osaka Red Cross
Hospital, Osaka; Masaya Okada, Division of Hematol-
ogy and Oncology, Department of Internal Medicine,
Hyogo College of Medicine, Hyogo; Masamichi Hara,
Division of Hematology, Ehime Prefectural Central
Hospital, Matsuyama, Japan.
